GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, ...

Insulin therapy can effectively control blood glucose levels in patients with diabetes. However, its use comes with the risk of inducing hypoglycaemia. Now, writing in Nature, Hoeg-Jensen et al. have ...

Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with ...

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...

Type 2 diabetes mellitus is a widespread disease, affecting millions of people globally. Although genetics and environmental factors seem to have a role, the cause of this metabolic disorder is ...

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study. Blocking ...

Developing resistance to insulin is a key step on the road to diabetes, making insulin resistance a target for treating metabolic dysfunction. Insulin orchestrates blood glucose levels by signaling ...

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for degradation. “Insulin was discovered 100 ...

A new study uncovers how endothelial cells contribute to insulin resistance in obesity-associated diabetes, highlighting adrenomedullin as a potential therapeutic target. Study: Endothelial insulin ...

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study by a team at the Max Planck Institute ...